Tubridge® Gains CFDA Approval

MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort"), recently gained the approval of China Food and Drug Administration ("CFDA") for its in-house developed Tubridge® Vascular Reconstruction Device ("Tubridge"). It is the fifth product of MicroPort® that obtained the CFDA approval through Green-Path, a fast-track approval process offered by CFDA for innovative medical devices.

Tubridge® is the first China-developed flow diverting stent that has obtained CFDA approval in China. It is designed for the treatment of large and giant cerebral aneurysm. Since the release of its results, Tubridge® successfully broke many technological hurdles such as densely meshed wire braids, and was selected as one of the projects in the National Key Technology R&D Program for China’s 12th Five-Year Plan. It is also the first flow diverting stent used in the clinical setting, researched via a hemodynamic approach, and studied in a randomized clinical trial, as well as the first neurovascular device obtained CFDA Green-Path status in China. With the approval from CFDA, MicroPort® will provide high quality medical devices by constant innovation to benefit patients with.
MicroPort® Vertebral Artery Rapamycin Target Eluting Stent System Granted CFDA Green-Path

Vertebral Artery Rapamycin Target Eluting Stent System of MicroPort® NeuroTech, a wholly owned subsidiary of MicroPort®, was granted to enter the special Green-Path by CFDA, which is rapid-track of review and approval procedure for innovative medical devices. Up to date, a total of 12 products in-house developed by MicroPort® and its subsidiaries have entered Green-Path.

In the cerebrovascular system, vertebral artery is the part most likely to have stenosis other than carotid artery bifurcation. However, there is no stent specially designed for the treatment of vertebral artery stenosis, so physicians have to use coronary drug-eluting stents or intracranial artery stents to treat vertebral artery stenosis.

Vertebral Artery Rapamycin Target Eluting Stent System is the world’s first drug-eluting stent indicated for the treatment of vertebral artery stenosis. The device design conforms to the anatomical features of vertebral artery, and it has excellent crossability and radial strength.

MicroPort® NeuroTech’s Tubridge® was granted CFDA Green-Path in 2015 and gained CFDA approval in March. It is expected that the CFDA Green-Path of Vertebral Artery Rapamycin Target Eluting Stent System will also shorten its approval time to benefit more patients.
Foxtrot™ NC PTCA Gains Regulatory Approval in Malaysia

MicroPort* recently gained the regulatory approval from Malaysia's Medical Device Authority ("MDA") for its in-house developed Foxtrot™ NC PTCA Balloon Catheter ("Foxtrot™ NC"). There are 60 specifications that were approved in Malaysia, covering 10 diameters (2.2mm to 5.0mm) and six lengths (6mm, 8mm, 10mm, 12mm, 15mm and 20mm).

Previously, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk") and Foxtrot™ Pro PTCA Balloon Catheter were approved to enter the Malaysia market. As Foxtrot™ NC also gained the regulatory approval, it will further diversify MicroPort’s cardiovascular product line in Malaysia and offer more comprehensive solutions for local patients. Meanwhile, it is expected to help MicroPort* further consolidate and expand its market share of cardiovascular products in Malaysia and other overseas markets.
Firehawk® Gains Regulatory Approval in Myanmar

MicroPort® received the regulatory approval from Myanmar authority for its in-house developed Firehawk®. It is the first time for MicroPort® products to gain regulatory approval in Myanmar. Firehawk® is the result of eight years of research and development of MicroPort® and it is the world’s first and only target-eluting stent ("TES").

Previously, Firehawk® gained CE mark, approval from China Food and Drug Administration and regulatory approval in more than 30 countries including India, Thailand, Indonesia, Brazil, Argentina, and Colombia. The approval of Firehawk® in Myanmar represents a milestone in the development of the local market as well as the market expansion of Firehawk®. In the future, MicroPort® will continue to offer more high quality medical device to the Myanmar market to benefit local patients.
**MicroPort® CardioFlow**

**Releases One-year Clinical Outcome of VitaFlow®**

MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow"), a wholly owned subsidiary of MicroPort®, attended CIT 2018 and released the one-year clinical outcome of VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®"). Academician Junbo Ge of Zhongshan Hospital of Fudan University for the first time released the one-year follow-up result of VitaFlow® which demonstrated that VitaFlow® is safe and effective in treating severe calcified aortic stenosis. After his presentation, experts in attendance had hot discussion on this clinical outcome and spoke highly of the excellent performance of VitaFlow® in treating BAV stenosis. Currently, VitaFlow® was granted the Green-Path by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval, and is expected to gain CFDA approval in 2018 to benefit domestic patients.
MPSC Announces 2017 Annual Results

MicroPort Scientific Corporation (HK: 853) ("MPSC" or the "Company") announced the audited annual results of the Company and its subsidiaries ("Group") for the 12 months ended December 31, 2017 ("reporting period"). During the reporting period, the Group successfully recorded the revenue of US$444.2 million, representing a growth of 14.7% excluding the foreign exchange impact. The Group recorded a profit attributable to equity shareholders of US$18.8 million (net profit of US$17.0 million) for the year ended December 31, 2017, with an increase of 33.1% as compared with that for the year ended December 31, 2016. In 2017, the medical device industry experienced rapid growth. Instead of relying on the cost and price advantages, Chinese companies now aims at building "Made in China" brand in the international market with their leading technologies, global vision, and rich experience in international operations.

The Group’s outstanding performance was mainly driven by strong sales performance of key business segments and products. Meanwhile, the Group has gained substantial advancements of key pipeline products in regulatory and clinical development. In addition, the Company signed some important financing and acquisition agreements which attracted great attention. These financing and M&A moves not only allow us to optimize the financial structure and support the ongoing development of various business sectors, but also expand our geographic reach and product portfolio, to build MPSC world’s leading medical technology company.

Dr. Zhaohua Chang said, that in 2018, the Group’s pipeline of various businesses continues to progress, with several products expected to gain regulatory approval followed by planned market launch, which will provide strong momentum of sustainable growth for the Company. We aim to continuously offer innovations, technologies and services to millions of global patients and become a patient-centric global enterprise in minimally invasive and other emerging medical market.
**MicroPort® Attends INDIA LIVE 2018**

MicroPort® recently attended the annual INDIA LIVE 2018 in India to display its in-house developed Firehawk®. During the meeting, a live case of Firehawk® was broadcasted to demonstrate its clinical performance. The postoperative OCT shows excellent outcome and the outstanding pushability and crossability of Firehawk® were highly recognized by physicians and experts in attendance.

India has the third largest amount of PCI cases in the world, and the market has been experiencing rapid development in recent years. During this meeting, MicroPort® took the opportunity to enhance communications with local experts and demonstrated its strength and growth potential to them. As Firehawk® and Firefighter™ PTCA Balloon Catheter (“Firefighter™”) have been gaining higher recognition among local patients and physicians, MicroPort® is enlarging its influence and market share in the Indian market. In the future, MicroPort® will further expand the Indian market to provide ideal medical solutions for local patients suffering from cardiovascular diseases.
MicroPort® Scientific India attended the Annual Arthroplasty Conference Hyderabad in India with more than 400 orthopedic surgeons from worldwide in attendance. MicroPort® Scientific India displayed MicroPort® Orthopedics products and attracted wide attention from the audience with its SuperPath® Micro-posterior Total Hip Arthroplasty ("SuperPath") and ADVANCE® Total Knee Replacement System ("ADVANCE"). Since the establishment of MicroPort® Scientific India in 2016, it has introduced Firehawk® and Firefighter™ PTCA Balloon Catheter ("Firefighter") to the India market. With the increasing awareness of MicroPort® brand in the local market, its cardiovascular products are gaining higher recognition among patients and physicians in India. As a country with the second largest population, India has a fast growing orthopedic market. According to statistics, in 2016 the market value of Indian orthopedic implant stood at USD375 million with an annual growth rate of 20% from 2017 to 2020. With the expansion of the orthopedic business in India, it is expected that the market share and brand awareness of MicroPort® will be further increased in India and other overseas market.
MicroPort® Attends CIT 2018

MicroPort® attended the China Interventional Therapeutics 2018 ("CIT 2018") that focuses on Cooperation, Innovation, and Transition. The symposium features MicroPort® innovative products of coronary interventional, electrophysiological, cardiac valves, and pacemaker business segments, which attracted wide attention from the audience. At the same time, the symposium was live broadcasted in MicroPort® headquarters, MicroPort® booth and Wechat to cover more audience.

The year 2018 marks the 20th anniversary of MicroPort®. Thus, the company displayed the development history of several business segments including cardiovascular, endovascular, electrophysiological, cardiac rhythm management, and surgical devices, based on the theme "MicroPort® 20 Years" in its CIT booth.

In this congress, MicroPort® displayed several innovative achievements in the cardiovascular intervention industry. As a leading high-end medical device company in China and the world, MicroPort® is dedicated to providing patients with safe, effective and affordable cardiac interventional solutions through constant innovation and integrating global experts' techniques and experience.
MicroPort® Orthopedics attended the 2018 Annual Meeting of Chinese Hip Society ("CHS"), which was jointly hosted by CHS and American Association of Hip and Knee Surgeons ("AAHKS"). In the congress, MicroPort® Orthopedics introduced the design rationale and advantages of SuperPath® through product samples, animation, surgical videos, and instrument demonstration. SuperPath® technique not only offers patients with small incision, but also preserves the soft tissue to the largest extent which leads to added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. Patients can walk as early as four hours after surgery. As it is in line with the main trend of the development of artificial joint replacement, the concept of "fast return to function" has been highly recognized by hospitals, clinical experts and medical enterprises. It improves not only the operative recovery for patients, but also the management efficiency of hospitals so as to save medical resources and serve more patients. In the future, MicroPort® Orthopedics will continue to promote SuperPath® technique and help drive the development of minimally invasive techniques and spread the philosophy of "fast return to function" to benefit more orthopedic patients.
MicroPort® Orthopedics Attends 2018 Qinling Joint Surgery Master Forum

MicroPort® Orthopedics® attended 2018 Qinling Joint Surgery Master Forum to display its hip and knee products through product samples, animation, surgical videos, and instrument demonstration. During the meeting, Professor Jia Zheng of Henan Province People Hospital was invited to introduce SuperPath® surgical technique to the attendees based on the study of knee biomechanics and its clinical experience. The distal portion of femur of Asian people is narrower than that of Western people due to the difference of skeletal structure. The medial pivot Stature® Femur is designed to fit in the anatomical features of Asian people. The medial pivot knee can also help resume the biomechanics of a natural knee to ensure the femur rotation during the flexion, which results in improved patient satisfaction after surgery.

MicroPort® Orthopedics Medial Pivot knee was launched in the US in 1998 with around 20 years’ clinical history. Up to date, nearly 550,000 Medial Pivot knees have been implanted globally. Several long-term studies have proved the advantages of medial pivot knee in total knee arthroplasty (“TKA”). With the aims to increase patient satisfaction, the medial pivot knee will serve more domestic and overseas patients. MicroPort® Orthopedics will continue to work with surgeons to provide better orthopedic solutions to patients, in accordance with our branding ideology "The Patient Always Comes First."
MicroPort® Endovascular Hosts
Endovascular Treatment of Aortic Disease Forum in CIT2018

MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the CIT 2018 and hosted Endovascular Treatment of Aortic Disease Forum. The Forum held discussion about Technical Evaluation for Endovascular Reconstruction of Branched Artery, Current Endovascular Methods to Treat Aortic Dissection, Case Reviews of Complex Thoracic Aortic Dissection, Treatment Strategy for Aortic Arch Disease, and Endovascular Treatment for AAA with Severe Iliac Artery Abnormity. This summit provided a platform for clinicians to exchange ideas, and at the same time, it showcased the endovascular solutions of MicroPort® Endovascular including Castor®, Talos™ and AB Unibody Stent.
CIT 2018: MicroPort® Hosts Twilight Symposium
"MicroPort® 20 Years – From Firehawk® to Firesorb®"

MicroPort® attended the CIT 2018 and hosted Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®", which attracted wide attention from the audience. The Symposium introduced the FUTURE-I research, which was the First-In-Man ("FIM") study on Firesorb®. Based on the two-year follow-up outcome, Firesorb® is one of the safe and effective solutions for patients with single-vessel coronary diseases. The Symposium also covered the new products and new technologies under research to demonstrate MicroPort® is an innovative, high-tech medical device group.

On March 24, MicroPort® hosted Twilight Symposium "MicroPort® 20 Years – From Firehawk® to Firesorb®". The Symposium released the three-month OCT result of Target AC Trial which shows the early healing effect of Firehawk® stents is non-inferior to that of the control group Xience stents. Afterwards, clinical cases of Firehawk® were reviewed, and they shows its excellent crossability and dilation ability. A case of Firehawk® treating left main disease under the guidance of intracavity imaging and physiological function examination was analyzed, which further demonstrated the excellent performance of Firehawk®.

This conference fully demonstrated the excellent performance of Firehawk® and verified the safety and efficacy of Firehawk® and Firesorb® with evidence based medicine.
MicroPort® Orthopedics Celebrates the 20th Year Anniversary for Market Launch of Medial Pivot Knee

MicroPort® Orthopedics held a ceremony to celebrate the 20th Year Anniversary for the market launch of its Medial Pivot Knee in Hainan Province. Around 50 renowned orthopedics experts were invited to attend the celebration, and to have academic exchanges regarding the development of Total Knee Arthroplasty while sharing their clinical experience with Medial Pivot Knee.

MicroPort® Orthopedics Medial Pivot knee was launched in the US in 1998 with around 20 years' clinical history. Up to date, nearly 550,000 Medial Pivot knees have been implanted globally. Several long-term studies have proved the advantages of medial pivot knee in total knee arthroplasty ("TKA").
First Implantation of Rega™ Family Implantable Pacemakers in China

The first batch of Rega™ Family Implantable Pacemakers has been implanted in several hospitals of more than six provinces to help patients with bradycardia resume normal life and activities. The domestically made pacemakers have world-class quality, but are 20% to 30% cheaper than the imported ones. Specifically, they are the smallest pacemakers available in market. In November 2017, MicroPort Scientific Corporation announce that it is expected to acquire the CRM Business Franchise from LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and upon completion of the acquisition, MicroPort® will become the most advanced domestic company in China with CRM know-how in the global CRM market. MSC will continue to serve the China market and develop CRM devices for the Chinese patients to help promote the development of CRM market in China.
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
**Tel:** (86)(21) 38954600  
**Email:** ir@microport.com

**Leanne Li**  
Board Secretary & VP of Corporate General Affairs  
MicroPort Scientific Corporation  
**Tel:** (86)(21) 38954600  
**Email:** ir@microport.com